DOI: 10.3724/SP.J.1008.2011.00005

Academic Journal of Second Military Medical University (第二军医大学学报) 2011/31:1 PP.5-8

Relationship of circulating Th17/Treg ratio with hepatitis B e-antigen loss in chronic HBV infection patients receiving enticarvir(ETV) antiviral treatment

Objective To investigate the relation of Treg/Th17 ratio with HBeAg loss in chronic HBV infection patients during enticarvir antiviral treatment. Methods The sera and peripheral blood mononuclear cells (PBMCs) were obtained from the enrolled chronic HBV infection patients and healthy controls at different time points of enticarvir antiviral treatment. The HBV markers, HBV-DNA, serum alanine transaminase(ALT), the HBV-specific IL-17 levels, and the frequencies of Th17, Treg cells in PBMCs were determined. Results HBV-DNA and Treg cell frequencies were decreased and the frequency of Th17 cells was rapidly increased in all patients; the secretion of IL-17 decreased upon specific stimulation with HBcAg. Therapy induced inhibition of HBV replication led to great decrease of Treg/Th17. The decrease of Treg/Th17 ratio was closely related to loss of serum HBeAg at the fourth week. Conclusion Inhibition of viral replication can not only reduce the activity of Th17 cells, but also quickly decrease the Treg/Th17 ratio. The Treg/Th17 ratio at the fourth week can serve as a marker for the effect of entacavir treatment for chronic hepatitis B.

Key words:hepatitis B,enticarvir,hepatitis B e-antigen,regulatory T-lymphocytes,Th17 cells

ReleaseDate:2014-07-21 15:40:21

Funds:Major Project of National Science and Technology (2008ZX10002-007)

[1] Chang T T,Gish R G,de Man R,Gadano A,Sollano J,Chao Y C,et al.A comparison of entecavir and lamivudine for HbeAg positive chronic hepatitis B[J].N Engl J Med,2006, 354:1001-1010.

[2] Lai C L,Shouval D,Lok A S,Chang T T,Cheinquer H,Goodman Z,et al.Entecavir versus lamivudine orpatients with HBeAg-negative chronic hepatitis B[J].N Engl J Med,2006,354:1863.

[3] Schroder K,Hertzog P J,Ravasi T,Hume D A.Interferon-gamma:an overview of signals,mechanisms and functions[J].J Leukoc Biol,2004,75:163-189.

[4] Stoop J N,van der Molen R G,Kuipers E J,Kusters J G,Janssen H L.Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B[J].Virology,2007,361:141-148.

[5] Zhang J Y,Zhang Z,Lin F,Zou Z S,Xu R N,Jin L,et al.Interleukin-17-producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B[J].Hepatology,2010,51:81-91.

[6] Yasumi Y,Takikawa Y,Endo R,Suzuki K.Interleukin-17 as a new marker of severity of acute hepatic injury[J].Hepatol Res,2007,37:248-254.

[7] Lemmers A,Moreno C,Gustot T,Maréchal R,Degré D,Demetter P,et al.The interleukin-17 pathway is involved in human alcoholic liver disease[J].Hepatology,2008,49:646-657.

[8] Oukka M.Interplay between pathogenic Th17 and regulatory T cells[J].Ann Rheum Dis,2007,66(Suppl 3):iii87-iii90.

[9] Weaver C T,Hatton R D.Interplay between the Th17 and Treg cell lineages:a (co)evolutionary perspective[J].Nat Rev Immunol,2009,9:883-889.